logo
Plus   Neg
Share
Email

5 Top Losers In Healthcare Sector (ENDP, AVGR, LPTX...)

pharmadown aug06 lt

The following are some of the healthcare stocks that posted the biggest percentage decline on Tuesday.

1. Miragen Therapeutics Inc. (MGEN)

miRagen Therapeutics is a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs.

Lost 28.88% to close Tuesday's (Aug.6) trading at $1.33.

News: No news

Clinical Trials & Near-term Catalyst:

The Company's lead drug candidate is Cobomarsen, which is under a phase II trial in patients with Cutaneous T-cell Lymphoma, dubbed SOLAR. Data from this trial is expected in the second half of 2020.

Cobomarsen is also being studied in phase I trials in the indications of adult T-cell leukemia/lymphoma (ATLL), chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL).

Also in the pipeline are Remlarsen (MRG-201) a potential treatment of patients with fibrotic diseases, and MRG-110 (S95010) for the treatment of cardiovascular disease.

MRG-201 is under a phase II clinical trial in subjects with a predisposition for keloid formation, and results from this study are expected in the second half of 2019. Two phase I clinical trials designed to evaluate the safety, tolerability, and pharmacokinetics of MRG-110 are underway, with data anticipated this year.

2. Endo International plc (ENDP)

Endo International is a generics and specialty branded pharmaceutical company.

Lost 21.05% to close Tuesday's trading at $2.25.

News: The Company reported a decline in earnings and revenue in the second-quarter 2019 financial results.

Adjusted income from continuing operations for the second quarter of 2019 declined to $120 million or $0.52 per share from $172 million or $0.76 per share in the year-ago quarter. Revenue in the recent second quarter declined to $700 million from $715 million in the comparable year-ago quarter.

Analysts polled by Thomson Reuters were expecting earnings of $0.48 per share and revenue of $695.9 million.

3. Equillium Inc. (EQ)

Lost 17.25% to close Tuesday's trading at $3.31.

News: No news

Clinical Trials & Near-term Catalysts:

The Company's lead drug candidate is Itolizumab (EQ001).

-- A phase Ib/II clinical trial of EQ001 in patients with acute graft-versus-host disease (aGVHD), dubbed EQUATE, is underway, with data expected in the first quarter of 2020.
-- A phase Ib proof-of-concept trials of EQ001 in uncontrolled asthma, dubbed EQUIP is underway, with topline data expected in the second half of 2020.
-- A phase Ib proof-of-concept trial of EQ001 for the treatment of lupus nephritis is expected to be initiated during the second half of 2019.

4. Avinger Inc. (AVGR)

Avinger is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease, or PAD.

Lost 15.29% to close Tuesday's trading at $1.44.

News: No news

Recent event:

-- On July 31, 2019, the Company reported financial results for the second quarter ended June 30, 2019.

Net loss attributable to common stockholders for the second quarter of 2019 narrowed to $5.55 million or $0.87 per share from $6.64 million or $9.83 per share in the year-ago quarter. Revenue for the recent second quarter increased to $2.32 million from $2.06 million in the year-earlier period.

-- On July 10, 2019, the Company announced that the 50th patient has been enrolled in its global, single-arm, multi-center study evaluating its Pantheris Lumivascular atherectomy system for treating in-stent restenosis (ISR) in lower extremity arteries. The study, dubbed INSIGHT, is designed to enroll up to 140 patients.

-- On June 21, the Company implemented a 1-for-10 reverse stock split of its common stock in order to secure NASDAQ listing.

5. Leap Therapeutics Inc. (LPTX)

Leap Therapeutics is focused on developing targeted and immuno-oncology therapeutics.

Lost 14.90% to close Tuesday's trading at $1.77.

News: The Company announced that its drug candidate DKN-01, in combination with Merck's blockbuster drug Keytruda demonstrated higher survival and objective response outcomes in patients with advanced gastroesophageal junction and gastric cancer (GEJ/GC) whose tumors expressed high levels of DKK1 (DKK1-high). Despite the promising results, the stock plunged on Tuesday.

Outlining the path forward for DKN-01, Leap Therapeutics, in a conference call, revealed that updated data will be presented in September 2019 and that its business strategy is to identify a partner for late-stage development of the compound.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT